Vertex Pharmaceuticals Incorporated $VRTX Stock Sold by Vestor Capital LLC

Vestor Capital LLC reduced its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 96.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 2,016 shares of the pharmaceutical company’s stock after selling 51,811 shares during the period. Vestor Capital LLC’s holdings in Vertex Pharmaceuticals were worth $1,054,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of VRTX. Kestra Investment Management LLC grew its position in shares of Vertex Pharmaceuticals by 10.3% during the 3rd quarter. Kestra Investment Management LLC now owns 760 shares of the pharmaceutical company’s stock worth $398,000 after buying an additional 71 shares during the period. AlphaCore Capital LLC grew its holdings in shares of Vertex Pharmaceuticals by 10.5% in the 3rd quarter. AlphaCore Capital LLC now owns 3,599 shares of the pharmaceutical company’s stock valued at $1,881,000 after buying an additional 341 shares during the period. Leuthold Group LLC increased its position in shares of Vertex Pharmaceuticals by 9.4% in the 3rd quarter. Leuthold Group LLC now owns 17,113 shares of the pharmaceutical company’s stock valued at $8,947,000 after buying an additional 1,473 shares in the last quarter. Joseph Group Capital Management increased its position in shares of Vertex Pharmaceuticals by 3.1% in the 3rd quarter. Joseph Group Capital Management now owns 11,085 shares of the pharmaceutical company’s stock valued at $5,795,000 after buying an additional 329 shares in the last quarter. Finally, Fulcrum Asset Management LLP acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth $290,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Trading Up 0.7%

VRTX opened at $550.87 on Tuesday. The stock has a market capitalization of $139.67 billion, a P/E ratio of 35.45, a P/E/G ratio of 2.84 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a 12 month low of $410.50 and a 12 month high of $568.67. The firm’s fifty day simple moving average is $522.98 and its 200 day simple moving average is $482.40. The company has a current ratio of 2.34, a quick ratio of 2.74 and a debt-to-equity ratio of 0.17.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The firm had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter last year, the company posted $4.80 EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 11.8% on a year-over-year basis. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current fiscal year.

Analysts Set New Price Targets

VRTX has been the topic of several recent analyst reports. TD Cowen lifted their target price on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a “buy” rating in a report on Tuesday, November 3rd. Wall Street Zen downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, October 31st. Daiwa Securities Group raised their price target on Vertex Pharmaceuticals from $555.00 to $556.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Morgan Stanley cut their price objective on Vertex Pharmaceuticals from $665.00 to $660.00 and set an “overweight” rating on the stock in a report on Tuesday, November 3rd. Finally, Stifel Nicolaus boosted their price objective on Vertex Pharmaceuticals from $500.00 to $563.00 and gave the company a “hold” rating in a research report on Tuesday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $596.44.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF).

Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Vertex serves patients in the United States and international markets, including Europe.